Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5865342 | 0.98 | CXCR4 (0.46) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| Sulfuric Acid SCHEMBL29036120 | 0.98 | CXCR4 (0.46) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| SCHEMBL435751 | 0.94 | CXCR4 (0.48) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| Hydrochloric Acid SCHEMBL29631987 | 0.92 | CXCR4 (0.47) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| Hydrochloric Acid SCHEMBL5865479 | 0.91 | CXCR4 (0.50) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| Trifluoromethanesulfonic Acid SCHEMBL29036126 | 0.90 | CXCR4 (0.43) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| SCHEMBL342435 | 0.88 | POLB (0.42) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 | |
| SCHEMBL10823165 | 0.86 | POLB (0.41) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM5 | |
| SCHEMBL7618304 | 0.86 | POLB (0.41) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM5 | |
| SCHEMBL27856922 | 0.85 | CXCR4 (0.38) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997462-A1 | ASSAYS FOR IMPROVING AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING ACCURACY | Selux Diagnostics Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| WO-2021007492-A1 | ASSAYS FOR IMPROVING AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING ACCURACY | SeLux Diagnostics, Inc. (US) | 2021-01-14 | — | — | WO | claimed |
| EP-1968598-B1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | claimed |
| US-7713987-B2 | Pyrimidine-2,4-diamines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | claimed |
| EP-1968598-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2008088303-A1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL, PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | claimed |
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | PHAMIDIPATI SOMASEKHAR | 2007-06-07 | — | — | US | claimed |
| WO-2007002345-A2 | METHOD FOR IMPROVING WATER SOLUBILITY OF CHITOSAN | BAUSCH & LOMB INCORPORATED (US) | 2007-01-04 | — | — | WO | claimed |
| EP-0396584-B1 | ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES | MICROBIOLOGICAL RES AUTHORITY (GB) | 1995-01-25 | — | — | EP | claimed |
| EP-0396584-A1 | ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES. | HEALTH LAB SERVICE BOARD (GB) | 1990-11-14 | — | — | EP | claimed |
| WO-1989005356-A1 | ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES | THE PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) | 1989-06-15 | — | — | WO | claimed |
| CN-121914038-A | Preparation method of 3- (piperazine-1-yl) propane-1-sulfonic acid | 山东万纳生物科技有限公司 | 2026-04-24 | — | — | CN | disclosed |
| CN-121914038-A | Preparation method of 3- (piperazine-1-yl) propane-1-sulfonic acid | 山东万纳生物科技有限公司 | 2026-04-24 | — | — | CN | disclosed |
| EP-4658247-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROCALCITONEMIA | Vivacelle Bio, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250101032-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. | 2025-03-27 | — | — | US | disclosed |
| EP-2062036-A1 | METHODS, CASSETTES, GELS AND APPARATUSES FOR ISOLATION AND COLLECTION OF BIOMOLECULES FROM ELECTROPHORESIS GELS | Life Technologies Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1910509-A1 | DEVICE FOR PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE AND METHOD OF USING THE SAME | Attogenix Biosystems Pte Ltd. (SG) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008028127-A1 | METHODS, CASSETTES, GELS AND APPARATUSES FOR ISOLATION AND COLLECTION OF BIOMOLECULES FROM ELECTROPHORESIS GELS | Life Technologies Corporation (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007011305-A1 | DEVICE FOR PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE AND METHOD OF USING THE SAME | ATTOGENIX BIOSYSTEMS PTE LTD. (SG) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | SYK, LYN, BTK | CXCR4 1951/4885SIGMAR1 2727/4885POLB 3247/4885 |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | DCK, DPYD, DTYMK | CXCR4 1337/4885SIGMAR1 4435/4885POLB 550/4885 |
| US-20250101032-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | CTSB, CTSE, CTSD | CXCR4 328/4885SIGMAR1 4723/4885POLB 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.